• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Grants to help target genomic variants

Grants to help target genomic variants

September 23, 2015
CenterWatch Staff

Six new grants from the National Institutes of Health will support researchers to develop new computational approaches for searching among millions of genomic variants to find those that make a difference in disease susceptibility or in other traits. The awards are for three years each, and total about $13 million, pending the availability of funds. They are administered by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute, both parts of NIH.

Comparing the genomes of many people suggests that there are tens of millions of genetic variants, or DNA spelling differences. For the last decade, scientists have used genome-wide association studies (GWAS) to find regions of the genome associated with diseases and traits. In GWAS, the genomes of thousands of people with and without a disease are compared to find the genomic regions containing variants that affect disease risk. Although GWAS may find hundreds of variants that appear to be associated with a disease, it remains a challenge to find out which variants actually have a role in the disease process, and what that role might be.

Most variants, including many that contribute to disease risk, response to drugs, and traits such as height, are in genomic regions that do not code for proteins. Those variants usually affect the regulation of genes, residing within “switches” in the genome that determine when and where proteins are made.

The researchers are developing computational approaches to combine many different sets of data to identify disease-causing variants or narrow down the set of candidate variants. They will use data from experiments to determine the accuracy of the computational predictions.

The following grants have been awarded (pending availability of funds):

  • Broad Institute of MIT and Harvard, Cambridge, Mass.; $2.6 million, three years
  • Broad Institute of MIT and Harvard; $2.5 million, three years
  • University of North Carolina, Chapel Hill; $2.2 million, three years
  • Stanford University, California; $1.4 million, three years
  • University of California, San Diego/Ludwig Institute for Cancer Research; $2.3 million, three years
  • University of Washington/UW Medicine, Seattle and HudsonAlpha Institute for Biotechnology, Alabama; $1.9 million, three years (supported by the National Cancer Institute).

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing